Can I Take Berberine with Egrifta (Tesamorelin)?
At a glance
- The pair / Combined effect on blood glucose is unknown
- Tesamorelin and glucose / HbA1c 6.5% or higher in 5% vs 1% on placebo by week 26 [1]
- Berberine and glucose / Fasting glucose -0.82 mmol/L, HbA1c -0.63% in 37 trials, 3,048 patients [2]
- Berberine and CYP enzymes / Inhibited CYP3A4, CYP2D6 and CYP2C9 at 900 mg daily for 14 days [3]
- Berberine status / Dietary supplement; no FDA-approved application lists it [4]
- Berberine long-term safety / Controlled lipid trials lasted 4 to 24 weeks [5]
- Bottom line / Opposing glucose effects with no measured net result
What does the Egrifta SV label say about blood sugar?
Tesamorelin is a growth hormone-releasing factor analogue approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. The label states it is not indicated for weight loss because its effect on weight is neutral [1].
Glucose intolerance and diabetes mellitus are listed as warnings. During trials, 5% of tesamorelin-treated patients reached an HbA1c of 6.5% or higher by week 26, against 1% on placebo, a hazard ratio of 3.3 (95% CI 1.4 to 9.6) [1]. The label directs prescribers to evaluate glucose status before starting, monitor periodically during treatment, consider stopping in patients who develop glucose intolerance and do not show a clear efficacy response, and check people with diabetes at regular intervals for worsening retinopathy [1].
Those figures come from a population that largely excluded diabetes. The two pivotal studies required a fasting blood glucose below 150 mg/dL and excluded people with type 1 or type 2 diabetes and anyone previously treated with insulin, oral hypoglycemic agents or insulin-sensitizing agents [1]. In the 412-patient 26-week study, glycemic measures did not differ significantly between tesamorelin and placebo [6], and the pooled analysis of 806 patients reported no clinically meaningful glucose differences [7].
What does berberine do to blood glucose?
Berberine is a plant alkaloid sold as an over-the-counter dietary supplement. A Drugs@FDA search returned no approved application listing it as the active ingredient, so it is not an FDA-approved treatment for diabetes, high cholesterol or weight loss [4].
The largest synthesis of its glucose data covers 37 randomized trials and 3,048 patients: fasting glucose fell 0.82 mmol/L (95% CI -0.95 to -0.70), HbA1c fell 0.63% (95% CI -0.72 to -0.53), and two-hour glucose fell 1.16 mmol/L, with no increase in total adverse events or hypoglycemia. The effect was larger when baseline glucose and HbA1c were higher [2]. Berberine also lowered LDL cholesterol by 0.46 mmol/L in a meta-analysis of 18 placebo-controlled trials (1,788 participants, 900 to 1,500 mg per day for 4 to 24 weeks) [5].
The glucose-lowering mechanism described in that meta-analysis comes from preclinical work: berberine inhibits voltage-gated potassium channels in pancreatic beta cells and promotes insulin secretion only under high-glucose conditions [2].
What happens when the two are taken together?
The combination has not been tested in humans that we could find, so the net effect on glucose cannot be calculated from group averages. Berberine's glucose-lowering effect was larger in people with higher starting glucose and HbA1c [2]. The tesamorelin HbA1c signal appeared in trial populations with a mean baseline HbA1c of 5.3% [1]. Neither result predicts what happens when berberine is taken with Egrifta SV.
CYP450: where berberine and the Egrifta label overlap
Berberine changes how quickly the liver clears some drugs. In a crossover study of 17 healthy men who completed it (18 enrolled), 300 mg three times daily for 14 days raised midazolam exposure about 40% (AUC to 140% of placebo, 90% CI 117 to 168%), increased the urinary dextromethorphan/dextrorphan ratio about ninefold and doubled the losartan/E-3174 ratio, indicating inhibition of CYP3A4, CYP2D6 and CYP2C9. The omeprazole and caffeine probes did not change significantly [3].
Higher exposure is theoretically possible for sensitive substrates of these enzymes, mainly drugs with a narrow therapeutic window. That is an inference from the probe results, not a documented interaction for any named drug other than cyclosporine. In 52 kidney transplant recipients given berberine 0.2 g three times daily for 3 months versus 52 on cyclosporine alone, cyclosporine trough levels rose 88.9% from baseline against 64.5% in controls, leaving final levels 29.3% higher with berberine; a six-patient kinetic study found a 34.5% rise in cyclosporine AUC [8].
The Egrifta SV label has its own CYP450 section. It states that growth hormone may alter the clearance of drugs metabolized by CYP450 liver enzymes, naming corticosteroids, sex steroids, anticonvulsants and cyclosporine, and tells prescribers to monitor for interactions [1]. Berberine raised cyclosporine levels in the transplant study, but the two effects together have not been measured [8][1].
Tesamorelin itself is a peptide, and the label reports no formal human metabolism studies [1]. In healthy subjects, tesamorelin changed simvastatin exposure by about -8% (simvastatin acid -15%) and ritonavir exposure by about -9%, which the label calls no significant impact [1].
Side effects and what is not established
Berberine's main side effects are gastrointestinal. Across the 12 lipid trials that reported them, GI adverse events ran 2% to 23% with berberine and 2% to 15% with placebo, and no serious adverse events were reported [5]. In the 2008 diabetes studies, 20 patients (34.5%) had transient GI effects [9]. Human studies of berberine have generally been short: controlled lipid trials lasted 4 to 24 weeks, and long-term safety remains unknown [5][10]. A 2026 toxicology review reports liver, kidney, cardiovascular and immune toxicity for Berberis alkaloids under specific doses and conditions [10].
On the tesamorelin side, the label also covers IGF-1: among people treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3, and the label asks prescribers to monitor IGF-1 levels [1].
Pregnancy is one setting where both raise flags. Tesamorelin is contraindicated in pregnancy [1]. The authors of the bilirubin-binding study advised that berberine-rich herbal products be avoided in jaundiced newborns and in pregnant women, based on laboratory and animal findings rather than a human pregnancy trial [11].
Frequently asked questions
Can you take berberine with Egrifta (tesamorelin)?
Does berberine change tesamorelin blood levels?
Will berberine reduce tesamorelin's effect on belly fat?
Can the combination cause low blood sugar?
Does berberine interact with HIV medicines taken alongside tesamorelin?
References
Show all 12 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y, et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045.
- Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-7.
- Drugs@FDA: FDA-Approved Drugs.
- Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023;83(5):403-427.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-72.
- Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-7.
- Ma J, Lan X, Luo X, Jing Y, Yin Y, Du H, et al. Balancing efficacy and risk: A toxicological review and safety transformation of Berberis plants and their alkaloids. Phytomedicine. 2026;162:158782.
- Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201-8.
- Zhao JV, Yeung WF, Chan YH, Vackova D, Leung JYY, Ip DKM, et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13(8).